Filing Flows › Comparisons › KPTI vs MGNX
Karyopharm Therapeutics vs Macrogenics: KPTI and MGNX compared
Karyopharm Therapeutics is the larger company: $33.4M of revenue in its latest quarter (Q2 2026) against $32.8M for Macrogenics (Q2 2026). Macrogenics is growing faster (+378% against -12% a year earlier). Macrogenics is more profitable, with an operating margin of -42.2% against -67.4%.
Where the money goes: KPTI and MGNX
Karyopharm Therapeutics (KPTI) · Q2 2026
Karyopharm Therapeutics, Q2 2026: revenue $33.4M (-12% year over year), operating margin -67.4%, net loss $67.0M, operating cash flow −$24.9M. The chart follows the revenue to costs, profit and cash.
Macrogenics (MGNX) · Q2 2026
Macrogenics, Q2 2026: revenue $32.8M (+378% year over year), operating margin -42.2%, net earnings $19.5M, operating cash flow −$40.7M. The chart follows the revenue to costs, profit and cash.
| Karyopharm Therapeutics (KPTI) | Macrogenics (MGNX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $33.4M | $32.8M |
| Revenue growth, Y/Y | -12% | +378% |
| Operating margin | -67.4% | -42.2% |
| Net earnings | −$67.0M | $19.5M |
| Net margin | -200.5% | 59.4% |
| Operating cash flow | −$24.9M | −$40.7M |
Where the revenue comes from
Karyopharm Therapeutics
- Product: $30.8M (92%)
- License and Other: $2.7M (8%)
Macrogenics
- Collaborative and other agreements: $25.5M (78%)
- Royalty revenue: $7.3M (22%)
Questions
Which is bigger, Karyopharm Therapeutics or Macrogenics?
Karyopharm Therapeutics is the larger company: $33.4M of revenue in its latest quarter (Q2 2026) against $32.8M for Macrogenics (Q2 2026).
Is Karyopharm Therapeutics or Macrogenics growing faster?
Macrogenics is growing faster (+378% against -12% a year earlier).
Which is more profitable, Karyopharm Therapeutics or Macrogenics?
Macrogenics is more profitable, with an operating margin of -42.2% against -67.4%.
More: Karyopharm Therapeutics earnings · how Karyopharm Therapeutics makes money · Macrogenics earnings · how Macrogenics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.